MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Create the #1 medical social network (Video/Pictures)
Global aggregator of choice for advanced medical technology business intelligence
Innovation & Royalty Aggregator
Royalty Pharma plc (NASDAQ:RPRX)
Finance & Acquisitions: Royalty Pharma
Immunomedics (NASDAQ:IMMU)
Organization & Developments: Immunomedics
Parents
Immunomedics (NASDAQ:IMMU)
Children
2017: Immunomedics and Seattle Genetics reach mutual agreement to dissolve previously agreed upon
2017: ImmunoMedics Should Be On Your Radar Before Phase 2 Breast Cancer Data Update - Immunomedics, Inc. (NASDAQ:IMMU)
2017: Seattle Genetics Announces Global License Agreement with Immunomedics for Sacituzumab Govitecan (IMMU-132), a Promising Late-Stage ADC for Solid Tumors
2018: Reader Inquiry: Is There Further Upside In Immunomedics?_seekingalpha.com
2019: Immunomedics must endure another delay as FDA rejects cancer drug citing manufacturing issues – Endpoints News
2020: Immunomedics Gets Early FDA Approval - Path To Profitability Still Treacherous
Diagnostic products
Jumps
*Key People: Immunomedics
Finance & Acquisitions: Immunomedics